APTO vs. TIL, PASG, AVRO, CVM, CRIS, IKNA, TSBX, GNTA, CRTX, and TARA
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Instil Bio (TIL), Passage Bio (PASG), AVROBIO (AVRO), CEL-SCI (CVM), Curis (CRIS), Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Genenta Science (GNTA), Cortexyme (CRTX), and Protara Therapeutics (TARA). These companies are all part of the "medical" sector.
Instil Bio (NASDAQ:TIL) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking.
Aptose Biosciences received 282 more outperform votes than Instil Bio when rated by MarketBeat users. Likewise, 65.62% of users gave Aptose Biosciences an outperform vote while only 52.51% of users gave Instil Bio an outperform vote.
60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are owned by institutional investors. 46.5% of Instil Bio shares are owned by insiders. Comparatively, 4.6% of Aptose Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Instil Bio is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Instil Bio presently has a consensus target price of $25.00, suggesting a potential upside of 133.86%. Aptose Biosciences has a consensus target price of $17.50, suggesting a potential upside of 1,694.87%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Instil Bio.
In the previous week, Aptose Biosciences had 3 more articles in the media than Instil Bio. MarketBeat recorded 5 mentions for Aptose Biosciences and 2 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.58 beat Aptose Biosciences' score of 0.44 indicating that Aptose Biosciences is being referred to more favorably in the news media.
Instil Bio has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Aptose Biosciences' return on equity of -51.27% beat Instil Bio's return on equity.
Summary
Aptose Biosciences beats Instil Bio on 11 of the 15 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
